Profilo
Sascha Bucher is currently an Independent Non-Executive Director at Tarsier Pharma Ltd. since 2018 and Head-Global Transactions at Roivant Sciences GmbH.
Former positions include Director at Sumitomo Pharma Switzerland GmbH and Deputy Head-Global M&A at Roche Holding AG from 2009 to 2016.
Education includes an MBA from Harvard Business School.
Posizioni attive di Sascha Bucher
| Società | Posizione | Inizio |
|---|---|---|
| TARSIER PHARMA LTD. | Direttore/Membro del Consiglio | 01/01/2018 |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Corporate Officer/Principal | - |
Precedenti posizioni note di Sascha Bucher
| Società | Posizione | Fine |
|---|---|---|
| ROCHE HOLDING AG | Corporate Officer/Principal | 01/01/2016 |
Myovant Sciences GmbH
Myovant Sciences GmbH BiotechnologyHealth Technology Engages in development and marketing of biopharmaceutical products | Corporate Officer/Principal | - |
Formazione di Sascha Bucher
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Roche Holding AG
Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Myovant Sciences GmbH
Myovant Sciences GmbH BiotechnologyHealth Technology Engages in development and marketing of biopharmaceutical products | Health Technology |
Tarsier Pharma Ltd.
Tarsier Pharma Ltd. BiotechnologyHealth Technology Operates as a clinical-stage company that develops and commercializes novel therapeutic treatments for autoimmune eye disease & inflammatory ocular diseases | Health Technology |
















